IFNA1 and B-cell chronic lymphocytic leukemia: Inhibition of IFN signaling may account in part for the apparent activation of CLL cells by ruxolitinib (Figure 3) and the curious platelet increases observed with ruxolitinib in the presence of ibrutinib (Figure 2A).4, 24